千金药业品牌怎么样 申请店铺

我要投票 千金药业在女性洗液行业中的票数:687 更新时间:2026-01-13
千金药业是哪个国家的品牌?「千金药业」是 株洲千金药业股份有限公司 旗下著名品牌。该品牌发源于湖南省株洲市,由创始人江端预在1993年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力千金药业品牌出海!将品牌入驻外推网,定制千金药业品牌推广信息,可以显著提高千金药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

千金药业怎么样

株洲千金药业股份有限公司,前身为株洲市中药厂,1993年进行股份制改造,2004年上市(股票代码:600479),千金药业系国家大中型中药制药企业。旗下拥有十三家控股子公司。

千金药业注册资本3.05亿元,2013年底,总资产达到18.88亿元。经济效益综合指标在湖南省医药行业同行中排名第一,位居国内中药行业前列。

公司拥有国内最大、工艺最成熟的中药片剂生产线,日产量为1200万片,年产量可达35亿片。硬件装备先进,达到国内领先水平。2009年12月,位于河西天元区栗雨工业园的千金女性健康产业基地正式投产,该基地建设属国家高新技术产业项目,占地200亩达产规模30亿元。

公司专注于女性健康产业,已形成女性健康系列产品。公司现有片剂、颗粒剂、硬胶囊剂等八个剂型,十三条生产线,全部通过GMP认证。主要产品有:妇科千金片(胶囊)、补血益母颗粒、养阴清肺糖浆、千金椿乳凝胶、痛经宁糖浆(胶囊)、乳癖康胶囊妇科调经片、千金宁洗液、千金止带丸、八珍益母片、加味逍遥丸、乳泉颗粒等。

公司现有14个独家产品,近50个生产批文,拥有各项专利206件。其中主导产品妇科千金片(胶囊)是国家中药保护品种、国家基本药物,国家医保目录甲类品种,《中国药典》收载品种,国家秘密技术项目,是唯一列入国家秘密技术的妇科中成药品种。

千金药业及下属子公司现有员工4000余人,其中总部员工1800余人,大专以上学历人员超过52%,平均年龄为29岁,在职职业药师40余名。公司建立了近千人的专业化特质营销队伍,在全国除西藏、台湾、香港、澳门外的30多个省市设有联络处。

公司“十二五”战略目标是:成为女性健康领域标杆企业,成为中药衍生领域品牌产品;实现集团公司年销售收入达40亿元;实现员工收入增长翻番;使千金药业成为“快乐千金”、“和谐千金”、“富裕千金”和“品牌千金”。

发展历程

▲1966年:在株洲市徐家桥永安仁药店后,株洲千金药业股份有限公司的前身——株洲市中药加工厂(即株洲市医药公司星火中成药加工厂)成立。生产参苏丸、五积散等产品;注册商标为“火炬”。

▲1968年:更名为株洲市六二六制药厂,开始生产町水糖浆剂、丸剂和片剂。

▲1973年:六二六制药厂搬迁到金钩山路的原市委党校校址。

▲1975年:更名为株洲市中药制药厂。

▲1976年:启动“妇科千金片”研制。

▲1979年:注册使用“牡丹”商标;同年,妇科千金片获得生产批文并开始试生产。

▲1981年:被株洲市政府列为关、停、并、转的对象;同年,妇科千金片消毒灭菌技术攻关获得成功。

▲1983年:“妇科千金片”被评为湖南省优质产品。

▲1984年:牡丹牌“脑乐静”被评为湖南省优质产品。

▲1985年:“妇科千金片”被国家医药管理局评为优质产品。

▲1987年:更名为株洲市中药厂。

▲1991年:妇科千金片荣获国优银质奖。

▲1993年:改组为株洲千金药业股份有限公司;同年,妇科千金片销往新加坡。

▲1994年:妇科千金片入选国家基本药物。

▲1995年:“千金”牌商标获国家工商局注册商标证书。

▲1996年:“妇科千金片”被认定为1995年度湖南名牌产品。

▲1998年:成立陇西药材分公司。同年,湘江药业股份有限公司成立,千金药业投资816万元,占总股本的51%。同年,株洲千金医药贸易有限公司成立,注册资本500万元,千金药业和湘江药业分别投资480万元和20万元。

Zhuzhou Qianjin Pharmaceutical Co., Ltd., formerly Zhuzhou traditional Chinese medicine factory, was transformed into a joint-stock company in 1993 and listed in 2004 (Stock Code: 600479). Qianjin pharmaceutical is a large and medium-sized national traditional Chinese medicine pharmaceutical enterprise. It has 13 holding subsidiaries. Qianjin pharmaceutical has a registered capital of 305 million yuan, and by the end of 2013, its total assets reached 1888 million yuan. The comprehensive index of economic benefit ranks the first among the medical industry peers in Hunan Province, and ranks in the forefront of the domestic traditional Chinese medicine industry. The company has the largest and most mature production line of traditional Chinese medicine tablets in China, with a daily output of 12 million tablets and an annual output of 3.5 billion tablets. The hardware equipment is advanced, reaching the leading level in China. In December 2009, the Qianjin women's health industrial base, located in Liyu Industrial Park, Tianyuan District, Hexi, was officially put into operation. The construction of the base is a national high-tech industrial project, covering an area of 200 mu and reaching a production scale of 3 billion yuan. The company focuses on women's health industry and has formed a series of women's health products. The company has eight dosage forms such as tablet, granule, hard capsule and thirteen production lines, all of which have passed GMP certification. The main products are: gynecological Qianjin tablets (capsules), blood enriching mother granule, Yangyin Qingfei syrup, Qianjin Chun milk gel, dysmenorrhea syrup (capsule), Rupikang capsule, gynecological regulating menstruation tablets, Qianjin Ning lotion, Qianjin Zhibao pills, eight Zhen Yi Mu tablets, Jiawei Xiaoyao pills, and Ruquan granules. The company has 14 exclusive products, nearly 50 production approvals and 206 patents. Among them, the leading product Fukeqianjin tablet (capsule) is the national traditional Chinese medicine protection variety, the national basic drug, the category a variety in the national medical insurance catalog, the variety included in the Chinese Pharmacopoeia, and the national secret technology project. It is the only variety of Chinese traditional medicine for gynecology listed in the national secret technology. Qianjin Pharmaceutical Co., Ltd. and its subsidiaries have more than 4000 employees, including more than 1800 employees in the headquarters, more than 52% of them with college degree or above, with an average age of 29 and more than 40 on-the-job professional pharmacists. The company has established a professional marketing team of nearly one thousand people, with liaison offices in more than 30 provinces and cities except Tibet, Taiwan, Hong Kong and Macao. The company's "12th Five Year Plan" strategic goal is: to become a benchmark enterprise in the field of women's health and a brand product in the field of traditional Chinese medicine derivatives; to realize the annual sales revenue of the group company reaching 4 billion yuan; to realize the doubling of the income growth of employees; to make Qianjin pharmaceutical industry become "happy Qianjin", "harmonious Qianjin", "rich Qianjin" and "brand Qianjin". Development history ▲ 1966: after xujiaqiao yong'anren drugstore in Zhuzhou City, Zhuzhou Qianjin Pharmaceutical Co., Ltd., the predecessor of Zhuzhou traditional Chinese medicine processing factory (i.e. Xinghuo traditional Chinese medicine processing factory of Zhuzhou pharmaceutical company), was established. Production of Shensu pill, Wuji powder and other products; the registered trademark is "Torch". In 1968, it was renamed Zhuzhou 626 pharmaceutical factory and began to produce machishui syrup, pills and tablets. ▲ 1973: the 626 pharmaceutical factory was moved to the original site of the Party School of the municipal Party committee of jinyushan road. ▲ 1975: renamed Zhuzhou traditional Chinese medicine pharmaceutical factory. ▲ 1976: launch the development of "gynecology Qianjin tablet". In 1979, "Peony" trademark was registered and used; in the same year, gynecology Qianjin tablet obtained production approval and began trial production. In 1981, it was listed by Zhuzhou municipal government as the target of "close, stop, merge and transfer"; in the same year, the disinfection and sterilization technology of gynecology Qianjin tablet was successfully tackled. ▲ in 1983, "gynecology Qianjin tablet" was rated as high quality product of Hunan Province. ▲ 1984: Peony brand "Naolejing" was rated as high quality product of Hunan Province. In 1985, "gynecology Qianjin tablet" was rated as a high-quality product by the State Administration of medicine. ▲ 1987: renamed Zhuzhou traditional Chinese medicine factory. ▲ 1991: Gynecology Qianjin tablet won the national excellent silver medal. In 1993, it was reorganized into Zhuzhou Qianjin Pharmaceutical Co., Ltd. in the same year, Qianjin tablets for gynecology were sold to Singapore. ▲ 1994: Gynecology Qianjin tablet was selected as the national basic drug. ▲ in 1995, "Qianjin" brand trademark obtained the registered trademark certificate of the State Administration for Industry and commerce. In 1996, "gynecology Qianjin tablet" was recognized as the famous brand product of Hunan in 1995. ▲ 1998: Longxi herbal medicine branch was established. In the same year, Xiangjiang Pharmaceutical Co., Ltd. was established. Qianjin pharmaceutical invested 8.16 million yuan, accounting for 51% of the total share capital. In the same year, Zhuzhou Qianjin Pharmaceutical Trading Co., Ltd. was established with a registered capital of 5 million yuan. Qianjin pharmaceutical and Xiangjiang pharmaceutical invested 4.8 million yuan and 200000 yuan respectively.

本文链接: https://brand.waitui.com/db288be38.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

碳酸锂期货创阶段新高,机构提示风险

受出口政策预期变化及供需格局改善等因素共同影响,碳酸锂期货价格大幅上涨。1月12日,碳酸锂期货主力合约开盘即触及涨停,价格突破15万元/吨关口,创阶段新高。多位机构人士表示,本轮上涨的直接催化来自出口退税政策调整引发的“抢出口”预期,叠加产业链库存处于低位,短期对价格形成明显支撑,但在涨幅迅速扩大的背景下,后续波动风险亦不容忽视。(证券时报)

34分钟前

新兴市场ETF资金流入规模创逾一年来最大

投资者上周继续涌入新兴市场股票和债券交易所交易基金(ETF)。这是此类ETF连续第12周录得资金流入。数据显示,截至1月9日当周,投资于多个新兴市场国家或特定国家的美国上市新兴市场ETF合计录得资金流入39.7亿美元,高于前一周的10.9亿美元,单周资金流入创逾一年来最大。其中,股票ETF流入39.6亿美元,债券ETF流入770万美元。总资产从4427亿美元增至4526亿美元。MSCI新兴市场指数上周涨1.6%,至1452.35点。(第一财经)

34分钟前

特朗普预计于本周面试美联储主席候选人里德尔

当地时间1月12日消息,美国总统特朗普将于15日就美联储主席一职面试贝莱德集团首席债券投资经理里克·里德尔。现有资料显示,里德尔是接替美联储主席杰罗姆·鲍威尔的最终候选人之一。鲍威尔2017年11月在特朗普第一任期内获得美联储主席提名,于2018年出任美联储主席并连任至今。不过,随着鲍威尔担任美联储主席后连续加息,特朗普2018年便开始公开指责鲍威尔,并商讨解雇鲍威尔。去年再度就任美国总统后,特朗普曾多次尝试干涉美联储货币政策决议。特朗普曾公开称鲍威尔是“太迟先生”,批评他降息时机太迟或降息幅度不够。(央视新闻)

34分钟前

Meta计划在Reality Labs部门裁员约10%,进一步转向人工智能

Meta Platforms计划在Reality Labs部门裁减约10%的岗位,推动公司资源从虚拟现实产品进一步转向人工智能可穿戴设备。一位了解Meta计划、但无权公开发言的知情人士透露,裁员预计将在本周进行。据12月份的报道,Meta首席执行官扎克伯格去年年底曾要求高管在Reality Labs部门内寻找削减预算的空间,包括削减部分虚拟现实和元宇宙产品。(新浪财经)

34分钟前

政策资本双轮驱动,脑机接口技术落地与商业化提速并进

高位截瘫患者意念操控设备等临床成果持续涌现;非侵入式领域“独角兽”强脑科技完成约20亿元重磅融资,创下全球该领域第二大融资纪录;政策层面再添关键支撑,四川明确侵入式脑机接口医疗服务价格。2026年开年,我国脑机接口产业迎来技术突破、资本加持与政策赋能的三重利好,商业化进程全面提速。业内人士认为,作为“十五五”规划建议明确的六大未来产业之一,多重利好共振下,脑机接口正加速从前沿黑科技迈向民生实用领域,千亿级产业生态雏形已渐显,产业发展进入战略机遇期。(中证网)

35分钟前

本页详细列出关于千金药业的品牌信息,含品牌所属公司介绍,千金药业所处行业的品牌地位及优势。
咨询